International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302"
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Therapeutic Use
- Acronyms PRISM2
- Sponsors LFB Biotechnologies
- 30 Nov 2017 Status changed from recruiting to discontinued.
- 13 Nov 2017 This trial was discontinued in France (end date: 2017-07-28), according to European Clinical Trials Database.
- 02 Aug 2017 This study has been discontinued in Germany as per European Clinical Trials Database record.